Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York. Show more

HUDSON COMMONS, NEW YORK, NY, UNITED STATES, 10001, New York, NY, 10001, USA

https://www.ovidrx.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

489M

52 Wk Range

$0.84 - $3.10

Previous Close

$2.62

Open

$2.65

Volume

2,243,221

Day Range

$2.62 - $2.88

Enterprise Value

340.9M

Cash

94.06M

Avg Qtr Burn

-13.9M

Insider Ownership

7.04%

Institutional Own.

74.04%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Soticlestat (OV935) Details Rare genetic disease, Rare diseases, Dravet syndrome, Lennox-Gastaut syndrome	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV329 (GABA-AT inhibitor) Details Infantile Spasms	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV329 (GABA-AT inhibitor) Details Tuberous Sclerosis Complex-Associated Seizures	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV329 (GABA-AT inhibitor) Details Epilepsy	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV4071 Details Parkinson’s disease and Lewy body dementia	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV888 (GV101) Details Cerebral cavernous malformation	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV935 (CH24H Inhibitor) Details Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV101 (gaboxadol) Details Rare genetic disease, Fragile X syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV350 Details Neurological and Neuropsychiatric indications	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details Genetic disorder, Rare genetic disease, Angelman Syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.